Diagnostics News and Research

RSS

OCD introduces VITROS 4600 Chemistry System for high-volume laboratories

Ortho Clinical Diagnostics (OCD) today announced the launch of the VITROS® 4600 Chemistry System, a state-of-the-art analyzer that delivers high-quality, reliable test results for mid- to high-volume laboratories using the same core technologies that drive reliability and efficiency throughout OCD's portfolio of products.

From Ortho-Clinical Diagnostics, Inc. 22 Jul 2011

IDEXX Laboratories second quarter revenues increase 13% to $317.9 million

IDEXX Laboratories, Inc., today reported that revenues for the second quarter of 2011 increased 13% to $317.9 million, from $281.5 million for the second quarter of 2010. Organic revenue growth, as defined below, was 8%.

22 Jul 2011

Financial Times examines product development partnerships developing drugs for neglected diseases

The Financial Times examines the rise of product development partnerships (PDPs), which are "non-governmental organizations that generate their own funding and build partnerships with universities, businesses, government and patients in low-income countries to develop new drugs, vaccines, prevention techniques and diagnostics for diseases such as tuberculosis, HIV, malaria, cholera and meningitis."

22 Jul 2011

Roche's cobas KRAS Mutation Test for colorectal cancer now available in Europe

Roche announced today that the cobas KRAS Mutation Test is now commercially available in Europe for use in colorectal cancer.

22 Jul 2011

Abbott's AACC workshops to showcase HIV and vitamin D diagnostics, lab informatics

Abbott announced its schedule of key workshops and scientific presentations at the American Association for Clinical Chemistry (AACC) annual meeting, July 24-28 in Atlanta.

22 Jul 2011

WHO warns against blood test kits for tuberculosis

According to a World Health Organization (WHO) warning Sunday, the widely used blood tests to detect tuberculosis (TB) are “dangerous” to patients because they are unreliable and can produce incorrect results. The WHO announced that it will issue an unprecedented recommendation against using such tests for the infectious lung disease that affects some 14 million people worldwide. As much as a third of the world's population is thought to harbor the bacteria that cause TB.

21 Jul 2011

Neogen develops new pathogen DNA detection method for E. coli strains

Neogen Corporation has announced the development of a breakthrough pathogen detection and identification technology that provides next day, DNA-specific test results for seven pathogenic E. coli strains. The technology could be adapted to target almost any bacterium of concern in almost any food sample type.

21 Jul 2011

Randox win Premier Healthcare Alliance contract for Quality Control

Randox Laboratories Ltd is proud to announce that in April 2011 we signed a multi-year agreement with the Premier Healthcare Alliance for the supply of Acusera Quality Control (QC) materials. The agreement will provide the 90,000 plus Premier members with access to our extensive range of quality control products and the benefits they offer clinical laboratories. When asked about the new agreement Laura Coyle Randox Business Manager for the USA revealed that ‘We look forward to strengthening our relationship with Premier and providing added value to their members’.

From Randox Laboratories Ltd. 21 Jul 2011

WHO warning increases opportunity for Biomagnetics urine based TB assay

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, and other innovative technologies, today announced that the World Health Organization ("WHO") on Sunday July 17, 2011 warned that the widely used blood tests to detect tuberculosis ("TB") are unreliable and "dangerous" to patients because they produce too many false negatives and positives.

21 Jul 2011

Alliqua acquires global license for wound care dressings from Noble Biomaterials

Alliqua, Inc., an advanced biomedical products company focused on the development and manufacturing of proprietary drug delivery and wound care technologies today announced that it has acquired from Noble Biomaterials, Inc. a 10 year exclusive global license for two wound care dressings, with an additional 10 year renewal option.

21 Jul 2011

WHO denounces TB blood tests in first-ever 'negative' policy recommendation

The WHO "called on Wednesday for an immediate halt to the use of blood tests to detect active tuberculosis, saying they were faulty and leave millions of people at risk," Reuters reports.

21 Jul 2011

Three flutemetamol clinical abstracts to be presented at 2011 Alzheimer's Association ICAD

Recent clinical research data reported that the investigational amyloid imaging agent [18F]Flutemetamol showed highly consistent image interpretation1 and showed comparable in vitro binding to the Pittsburgh Compound-B investigational imaging agent3.

21 Jul 2011

Quest Diagnostics second quarter revenues increase 1.5% to $1.9 billion

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, announced today that for the second quarter ended June 30, 2011, adjusted income from continuing operations was $179 million, or $1.12 per share.

From Quest Diagnostics 20 Jul 2011

MDI, Eldan partner to distribute Detect-Ready MRSA Panel in Israel

Molecular Detection Inc. (MDI), a company developing Detect-Ready tests designed to increase the speed and accuracy of infectious disease diagnosis, and life sciences and diagnostics distributor Eldan, a part on the Neopharm Group, today announced that they have entered into an exclusive agreement for distribution of MDI's Detect-Ready MRSA Panel in Israel and the Palestinian territories.

20 Jul 2011

Medco announces new offerings within Advanced Oncology Solutions

Medco Health Solutions, Inc. today announced new offerings within its Advanced Oncology Solutions, that include treatment pathways decision support with embedded pharmacogenomic testing and nutrition recommendations for cancer patients.

20 Jul 2011

Promega PowerPlex 18D System receives approval for generating DNA records for NDIS

Promega PowerPlex® 18D System is now approved for use in laboratories generating DNA records for the National DNA Index System (NDIS). NDIS is the U.S. national database containing over seven million offender and forensic DNA profiles used to help authorities identify criminals nationwide.

20 Jul 2011

Johnson & Johnson second quarter sales increase 8.3% to $16.6 billion

Johnson & Johnson today announced sales of $16.6 billion for the second quarter of 2011, an increase of 8.3% as compared to the second quarter of 2010.

19 Jul 2011

EPA to expand Cooperative Research And Development Agreement with NanoLogix

NanoLogix, a biotechnology innovator in the rapid detection and identification of live-cell bacteria and microorganisms, announced today the U.S. Environmental Protection Agency (EPA) intends to expand its Cooperative Research And Development Agreement (CRADA) with NanoLogix to include additional water-borne pathogens.

19 Jul 2011

Medically treated patients with GERD more likely to develop esophageal cancer

Medically treated patients with mild or no symptoms of gastroesophageal reflux disease (GERD) are at higher risk for developing esophageal cancer than those with severe GERD symptoms, according to a University of Pittsburgh study published in the current issue of Archives of Surgery.

19 Jul 2011

Mayo Clinic licenses M. tuberculosis complex speciation test from QIAGEN

Mayo Clinic has licensed patent rights from QIAGEN to enable Mayo Medical Laboratories to offer an M. tuberculosis complex speciation test. The test expands Mayo Medical Laboratories' current offering for tuberculosis testing, which already includes M. tuberculosis complex culture, molecular identification and drug susceptibility testing.

From QIAGEN Manchester Limited 19 Jul 2011